Hosted on MSN22d
AbbVie's SWOT analysis: biopharmaceutical giant navigates post-Humira landscape
AbbVie (NYSE:ABBV) continues to navigate the challenges of Humira's loss of exclusivity while leveraging its diverse portfolio and robust pipeline to drive future growth. With a gross profit ...
Morningstar21d
AbbVie's Skyrizi and Rinvoq Have Revived Growth Beyond Humira, Supporting a Wide Moat
AbbVie holds a strong portfolio of marketed and pipeline drugs. While the increasing competition to the company's key drug Humira should slow the growth for the company in the near term ...
MarketWatch21d
AbbVie’s newer immunology drugs are offsetting Humira’s decline, sending stock up 5%
AbbVie Inc.’s stock rose 7.7% Friday to lead ... delivered growth needed to offset declining sales of its blockbuster Humira. The stock is on track for its biggest one-day percentage increase ...